Compare HXL & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HXL | IMVT |
|---|---|---|
| Founded | 1946 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 7.3B |
| IPO Year | 1994 | 2019 |
| Metric | HXL | IMVT |
|---|---|---|
| Price | $96.87 | $38.81 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 8 |
| Target Price | ★ $88.30 | $33.00 |
| AVG Volume (30 Days) | 879.8K | ★ 1.5M |
| Earning Date | 04-22-2026 | 05-28-2026 |
| Dividend Yield | ★ 0.80% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,893,900,000.00 | N/A |
| Revenue This Year | $10.09 | N/A |
| Revenue Next Year | $12.33 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $56.20 | $14.32 |
| 52 Week High | $101.51 | $38.90 |
| Indicator | HXL | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 57.69 | 72.32 |
| Support Level | $81.10 | $25.13 |
| Resistance Level | $97.69 | N/A |
| Average True Range (ATR) | 3.24 | 1.50 |
| MACD | 0.14 | 0.51 |
| Stochastic Oscillator | 65.65 | 94.14 |
Founded in 1948, Hexcel designs and manufactures a range of highly engineered composite fibers, fabrics, resins, and structures for use primarily in the commercial aerospace and defense markets. These are lighter than metal and perform under rigorous conditions in aircraft frames, wings, engine nacelles, and other structures and subassemblies. The company's name derives from the six-sided honeycomb structures that lend many of its products their light weight and rigidity. Hexcel's biggest customers are Airbus (40% of 2024 sales) and Boeing (15% of 2024 sales; 25% before the pandemic) and their respective subcontractors.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.